Genome-wide characterisation of hepatitis B mutations involved in clinical outcome

Heredity

Volumn 97, Issue 6, 2006, Pages 389-397

  Szmaragd, C ^a   Foster, G R ^b   Manica, A ^a   Bartholomeusz, A ^c   Nichols, R A ^d   Balloux, F ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Generalised linear model; Genotype phenotype link; Phylogenetics; Statistical modelling; Viral infection

Indexed keywords

DNA DIRECTED DNA POLYMERASE; DNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

EVOLUTION; GENOME; HEPATITIS; MUTATION; PHYLOGENETICS; POLYMORPHISM; VIRAL DISEASE;

AGE DISTRIBUTION; ARTICLE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MUTATION; PATHOGENICITY; PHYLOGENY; SEQUENCE ALIGNMENT; SEX RATIO; VIRUS GENOME;

AGE DISTRIBUTION; DNA-DIRECTED DNA POLYMERASE; DNA-DIRECTED RNA POLYMERASES; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MUTATION; PHYLOGENY; SEQUENCE ALIGNMENT; SEX DISTRIBUTION; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 33845213809     PISSN: 0018067X     EISSN: 13652540     Source Type: Journal    
DOI: 10.1038/sj.hdy.6800882     Document Type: Article

References (66)

1. Bartholomeusz A, Locarnini S (2001). Hepatitis B virus mutants and fulminant hepatitis B: Fitness plus phenotype. Hepatology 34: 432-435.
2. Bartholomeusz A, Locarnini S, Ayres A, Thompson G, Sozzi V, Angus P et al (2004). Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 40: 246A.
3. Blackberg J, Kidd-Ljunggren K (2000). Genotypic differences in the hepatitis B virus core promoter and precore sequences during seroconversion from HBeAg to Anti- HBe. J Med Virol 60: 107-112.
4. Carman W (1997). The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepatitis 4: 11-20.
5. Carman W, Boner W, Fattovich G, Colman K, Dornan E, Thursz M et al (1997). Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. J Infect Dis 175: 1093-1100.
6. Carman W, Jacyna M, Hadziyannis S, Karayiannis P, McGarvey M, Makris A et al (1989). Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2: 588-589.
7. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M et al (1998). Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27: 1711-1716.
8. Chevenet F (2006). TreeDyn: towards dynamic graphics & annotations for trees analyses V194.3 [http://www.treedyn.org].
9. Choi B, Parker G, Rho H (1999). Interaction of hepatitis B viral X protein and CCAAT/ enhancer-binding protein alpha synergistically activates the hepatitis B viral enhancer II/pregenomic promoter. J Biol Chem 29: 2858-2865.
10. Cromeans T, Fields H, Sobsey M (1989). Replication kinetics and cytopathic effect of hepatitis A virus. J Gen Virol 70: 2051-2062.
11. Cunningham C (1997). Can three incongruence tests predict when data should be combined? Mol Biol Evol 14: 733-740.
12. Dumpis U, Mendy M, Hill A, Thursz M, Hall A, Whittle H et al (2001). Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. J Med Virol 65: 664-670.
13. Edmunds W, Medley G, Nokes D, Hall A, Whittle H (1993). The influence of age on the development of the hepatitis-B carrier state. Proc R Soc Lond Ser B-Biol Sci 253: 197-201.
14. Edmunds W, Medley G, Nokes D, OCallaghan C, Whittle H, Hall A (1996). Epidemiological Patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117: 313-325.
15. Fares M, Holmes E (2002). A revised evolutionary history of hepatitis B virus (HBV). J Mol Evol 54: 807-814.
16. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G et al (1991). Identification of immunodominant Tcell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88: 214-222.
17. Ferrari C, Cavalli A, Penna A, Valli A, Bertoletti A, Pedretti G et al (1992). Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology 103: 255-263.
18. Fung S, Lok A (2004). Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 40: 790-792.
19. Ganem D (1996). Hepadnaviridae and their replication. In: Fields B, Knipe D and Howley P (eds) Virology, 3rd edn. Lippincott-Raven Publishers: New York. pp 2703-2737.
20. Gerner P, Lausch E, Friedt M, Tratzmuller R, Spangenberg C, Wirth S (1999). Hepatitis B virus core promoter mutations in children with multiple anti-HBe/HBeAg reactivations result in enhanced promoter activity. J Med Virol 59: 415-423.
21. Gripon P, Cannie I, Urban S (2005). Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 79: 1613-1622.
22. Gunther S (2000). Naturally occurring mutations of hepatitis B virus and outcome of chronic infection: Is there an association? Commentary Eur J Clin Invest 30: 751-753.
23. Gunther S, Paulij W, Meisel H, Will H (1998). Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity. Virology 244: 146-160.
24. Hannoun C, Horal P, Lindh M (2000). Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 81: 75-83.
25. Hasegawa K, Huang J, Rogers S, Blum H, Liang T (1994). Enhanced replication of a hepatitis-B virus mutant associated with epidemic of fulminant hepatitis. J Virol 68: 1651-1659.
26. Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag C et al (2002). Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 360: 991-995.
27. Hou J, Lin Y, Waters J, Wang Z, Min J, Liao H et al (2002). Detection and significance of a G1862T variant of hepatitis B virus in Chinese patients with fulminant hepatitis. J Gen Virol 83: 2291-2298.
28. Howard C (2002). Hepatitis viruses: a Pandora's box? J Gastroenterol Hepatol 17: S464-S467.
29. Jazayeri M, Basuni A, Sran N, Gish R, Cooksley G, Locarnini S et al (2004). HBV core sequence: definition of genotype-specific variability and correlation with geographical origin. J Viral Hepatitis 11: 488-501.
30. Kao J (2002). Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 17: 643-650.
31. Kao J, Chen P, Lai M, Chen D (2000). Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118: 554-559.
32. Kao J, Chen P, Lai M, Chen D (2002). Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 40: 1207-1209.
33. Kekule A, Lauer U, Meyer M, Casselmann W, Hofschneider P, Koshy R (1990). The preS2/s region of integrated hepatitis-B virus DNA encodes a transcriptional transactivator. Nature 343: 457-461.
34. Kidd-Ljunggren K, Miyakawa Y, Kidd A (2002). Genetic variability in hepatitis B viruses. J Gen Virol 83: 1267-1280.
35. Koseki T, Hongo S, Muraki Y, Sugawara K, Matsuzaki Y, Nakamura K (1999). Sequence analysis of the entire genome of hepatitis B virus from a patient with fulminant hepatitis. Yamagata Med J 17: 27-40.
36. Kramvis A, Kew M (2005). Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepatitis 12: 456-464.
37. Kumar S, Tamura K, Nei M (2004). Mega3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Briefings Bioinformat 5: 159-163.
38. Kuroki K, Floreani M, Mimms L, Ganem D (1990). Epitope mapping of the Pres1 domain of the hepatitis-B virus large surface protein. Virology 176: 620-624.
39. Lin TM, Chen CJ, Wu MM, Yang CS, Chen JS, Lin CC et al (1989). Hepatitis-B virus markers in Chinese twins. Anticancer Res 9: 737-741.
40. Lin X, Qian G, Lu P, Wu L, Wen Y (2001). Full length genomic analysis of hepatitis B virus isolates in a patient progressing from hepatitis to hepatocellular carcinoma. J Med Virol 64: 299-304.
41. Lindh M, Horal P, Dhillon A, Furuta Y, Norkrans G (1996). Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 24: 494-501.
42. Manica A, Prugnolle F, Balloux F (2005). Geography is a better determinant of human genetic differentiation than ethnicity. Hum Genet 118: 366-371.
43. Mayerat C, Mantegani A, Frei P (1999). Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepatitis 6: 299-304.
44. McIntosh E, Givney R, Zhang S, Courouce A, Burgess M, Cossart Y (1998). Molecular epidemiology and variation of hepatitis B in recent immigrant families to Australia. J Med Virol 56: 10-17.
45. Meisel H, Sominskaya I, Pumpens P, Pushko P, Borisova G, Deepen R et al (1994). Fine mapping and functional characterization of 2 immunodominant regions from the PreS2 sequence of hepatitis B virus. 37: 330-339.
46. Oess S, Hildt E (2000). Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Therapy 7: 750-758.
47. Preikschat P, Meisel H, Will H, Gunther S (1999). Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol 80: 2685-2691.
48. Previsani N, Lavanchy D (2002). Hepatitis B: World Health Organization, Department of Communicable Diseases Surveillance and Response [http://www.who.int/csr/en/].
49. R Core Development Team (2004). A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna.
50. Raney A, Le H, McLachlan A (1992). Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor. J Virol 66: 6912-6921.
51. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M et al (1995). The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181: 1047-1058.
52. Schaefer S (2005). Hepatitis B virus: significance of genotypes. J Viral Hepatitis 12: 111-124.
53. Shaul Y, Ben-Levy R, De-Medina T (1986). High affinity binding site for nuclear factor I next to the hepatitis B virus S gene promoter. Embo J 5: 1967-1971.
54. Simmonds P, Midgley S (2005). Recombination in the genesis and evolution of hepatitis B virus genotypes J. Virol 79: 15467-15476.
55. Sohn J, Lee C, Lee J, Lee K, Son C, Lee J et al (2005). Mutation analysis of hepatitis B virus promoters in chronically infected children. Arch Virol Suppl 150: 1639-1651.
56. Swofford D (2002). PAUP*. Phylogenetic Analysis Using Parsimony (*and Other Methods) 4.0b10 edn. Sinauer Associates: Sunderland, MA.
57. Szmaragd C, Nichols R, Balloux F (2006). A novel approach to characterise pathogen candidate mutations involved in clinical outcome. Infect Genet Evol 6: 38-45.
58. Thursz M (2001). Genetic susceptibility in chronic viral hepatitis. Antiviral Res 52: 113-116.
59. Tiollais P, Pourcel C, Dejean A (1985). The Hepatitis-B virus. Nature 317: 489-495.
60. Torre F, Naoumov N (1998). Clinical implications of mutations in the hepatitis B virus genome. Eur J Clin Invest 28: 604-614.
61. Torresi J (2002). The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25: 97-106.
62. Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini S et al (2002). Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293: 305-313.
63. Tsubota A, Kumada H, Takaki K, Chayama K, Kobayashi M, Kobayashi M et al (1998). Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen positive asymptomatic healthy carriers. J Med Virol 56: 287-293.
64. Venables W, Ripley B (1999). Modern Applied Statistics with S. Springer: New York.
65. Weinberger K, Bauer T, Bohm S, Jilg W (2000). High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 81: 1165-1174.
66. Xu Z, Yen T (1996). Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol 70: 133-140.